Interim CEO and CFO · Xenetic Biosciences, Inc. · Common Stock
Side
A
Value
—
Shares
100.0K
Price
—
Executed
Apr 21, 2026
Disclosed
Apr 23, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Apr 21 executedApr 23, 2026 disclosed
XBIO · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
Pre-arranged plan-10
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Other disclosed activity · XBIO
No records
No other disclosures for this security in the dataset.
Evidence
Verified data
Read directly from the primary public document; every field below is as reported by the filer.
Parslow James F filed this Form 4 reporting a grant or award of XBIO on Apr 21, 2026. It became public on Apr 23, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Interim CEO and CFO
Parslow James Fcik:0001285943
Issuer
Xenetic Biosciences, Inc.cik:0001534525
Revision history · 0
No field has changed since this record was first ingested.
